AMPLY DISCOVERY EXPLAINS HOW ITS AI TECHNOLOGY CAN IDENTIFY NOVEL BIOLGICAL DRUG CANDITATES

CEO, Ben Thomas, and CCO, Dermot Tierney, joined Moira Gunn from BioTech Nation to discuss exactly why the company was formed and how, with the assistance of AI and machine learning, it’s technology can identify novel biological drug and nutraceutical candidates

Click here to listen.

Podcast taken from: https://www.biotechnation.com/episodes/why-do-ai-one-way-when-you-can-do-it-25-dr-ben-thomas-and-dermot-tierny-ceo-cco-amply-discovery

Share the Post:

Related Posts

CFM and Ilimex

ILIMEX Announces Conclusion of Funding Round Raising £600,000 (c.€700,000) In Equity Finance

ILIMEX, the Northern Ireland-based provider of biosecurity and air sterilisation solutions, is pleased to announce the conclusion of a funding round which has raised additional equity finance of £600,000 (c. €700,000). This funding will be used to validate the performance of ILIMEX’s Flufence air sterilisation solutions and fund its entry into the agri-food sector with an initial focus on poultry and medicinal mushroom production.

Read More

Join Clarendon Fund Managers as Portfolio and Finance Manager

Clarendon Fund Managers, a B Corp-certified venture capital firm based in Belfast, is looking for a Portfolio and Finance Manager to join our growing team. With a mission to back high-potential companies and drive economic growth in Northern Ireland, we support a diverse and inclusive culture where collaboration, impact and excellence are at the core of what we do.

Read More